Mid Pharma Archives | Report Store

show blocks helper

Sort by Default Order
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products descending

Display 15 Products per page

Gilead Company Analysis

$3,000.00

PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
April 16, 2020
Find out more
GlaxoSmithKline

$3,000.00

PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
April 16, 2020
Find out more
Allergan

$3,000.00

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 10, 2018
Find out more
Celgene

$3,000.00

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 8, 2018
Find out more
UCB Company Analysis

$3,000.00

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
September 21, 2018
Find out more
Biogen

$3,000.00

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
September 4, 2018
Find out more
Lundbeck

$3,000.00

PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
August 24, 2018
Find out more
Merck KGaA Company Analysis

$3,000.00

PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
August 24, 2018
Find out more
AbbVie

$3,000.00

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2017–27.
February 28, 2018
Find out more
Acorda Company Analysis

$3,000.00

PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.
February 9, 2018
Find out more
BioMarin Company Analysis

$3,000.00

PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
January 4, 2018
Find out more
Incyte Company Analysis

$3,000.00

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
January 4, 2018
Find out more
Biogen

$3,000.00

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2017–27
March 7, 2017
Find out more
Actelion

$3,000.00

Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 1, 2016
Find out more
Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
September 28, 2016
Find out more

Mid Pharma

Mid Pharma

Gilead Company Analysis

GlaxoSmithKline

Allergan

Celgene

UCB Company Analysis

Biogen

Lundbeck

Merck KGaA Company Analysis

AbbVie

Acorda Company Analysis

BioMarin Company Analysis

Incyte Company Analysis

Biogen

Actelion

Mid Pharma Outlook